November 13, 2019
ProteKt Therapeutics, a biotech company developing new PKR kinase inhibitor based therapies for neurodegenerative diseas...
September 30, 2019
ASLAN spins out pre-clinical assets in joint venture with Bukwang to form JAGUAHR Therapeutics with Bukwang investin...
July 25, 2019
Dr Jean Bousquet, a renowned expert in pulmonary allergy, has delivered a keynote lecture on the next generation guideli...
July 10, 2019
3 million dollars invested by Medici Investment
European Clinical phase 2 study of JM-010 to treat dyskinesia i...
July 5, 2019
The sales of Dexid for diabetic polyneuropathy, Legalon for liver disease, and Entecavir for chronic hepatitis B are boo...
July 3, 2019
The University of Dundee‘s Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based B...
July 1, 2019
Bukwang’s successful launch of Neomed toothpaste on home-shopping marked its expansion on OTC business.
June 28, 2019
BNO BIO has invested $1 million in Nucleix, an Israeli bio-venture
The first global investment by BNO BIO since...
June 26, 2019
- to be completed within 2 years
Bukwang Pharmaceutical (“Bukwang”) announced today that the phase 2 clinical study of JM...
December 17, 2018
- Fast speed of study progression, expecting results in January next year
MLR-1023’s phase 2b study is completed on Decem...
Older Posts >
ProteKt Therapeutics Raises $3.6 Million in Post-incubation Financing
ASLAN PHARMACEUTICALS AND BUKWANG PHARMACEUTICAL ESTABLISH A JOINT VENTURE, JAGUAHR THERAPEUTICS, TO DEVELOP NOVEL IMMUNO-ONCOLOGY THERAPIES
Bukwang Pharmaceutical hosted a keynote lecture by a renowned expert in pulmonary allergy
Contera Pharma, a subsidiary of Bukwang Pharmaceutical, attracts investment from Medici Investment
Bukwang’s representative ethical products outperformed
University of Dundee partners with Bukwang Pharmaceutical Company to tackle new drug treatment for Parkinson’s disease.
Bukwang successfully launched Neomed toothpaste on home-shopping network
BNO BIO, a joint company by Bukwang and OCI, invests in a bio-venture that develop a technology in early detection of cancer
Bukwang Announced commencement of Phase 2 Clinical Study of JM-010 in major European countries
Bukwang Announces Completion of MLR-1023’s Phase 2b clinical trial